Navigation Links
China Pharma Holdings, Inc. Announces Clinical Trials Already Underway for Candesartan
Date:2/11/2009

HAIKOU CITY, China, Feb. 11 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, announced today that the company has initiated clinical trials for the generic version of the leading hypertension drug Candesartan.

The clinical trials for this product are anticipated to require approximately 18 months to complete. The sartan group of drugs, used as front- line therapy in the treatment of hypertension, are usually well-tolerated, and have a high safety record. Candesartan was discovered and originally synthesized by the Japanese firm, Takeda Pharmaceutical Company Limited and jointly developed by the same company with AstraZeneca. Worldwide sales for 2007 exceeded $2.5 billion(1). In China, Candesartan is listed on the National Basic Medical Insurance Drug List, enabling patient reimbursement.

China Pharma's CEO and president, Ms Zhilin Li, commented, ''In China today, nearly 60% of all urban adults aged 65 years and over suffer from hypertension(2). Moreover, due to the aging of the population and changes in lifestyle, the urban prevalence of hypertension has been predicted to grow to 100 million by 2011(2). Even in 2004, sales in China of anti-hypertension drugs exceeded CNY 10 billion ($1.2 billion, Dec. 2004), exhibiting a market growth of over 30% year on year, and accounting for 22% of all cardiovascular system drugs sold in China(3). Hypertension is a serious problem and is linked to an increased incidence of other diseases, particularly brain edema, coronary heart disease and diabetes. Candesartan is a well established hypertension drug and is known to be particularly suitable for heart failure and diabetic patients. Our R&D strategy is to enable us to provide more effective treatment for the high numbers of patients in China whose medication needs are seriously unmet so we are very happy that we will have this opportunity to provide better health for individuals suffering hypertension in China.''

About the drug. Candesartan lowers hypertension by inhibiting blood vessel constriction through blocking angiotensin II receptors.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Bio- pharmaceutical Co., Ltd (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .

Safe Harbor Statement: Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

    (1) Source: (for year ended March 31 2008) Takeda Pharmaceutical Company
        Ltd., Annual Report 2008.
    (2) Source: Nature Reviews, Drug Discovery: 2008 May; 7 383-384. Susan
        Ward. Demographic Factors in the Chinese Health-care Market
    (3) Source: Southern Medical Economic Research Institute: 2006, Dec.
        Sartan Drugs: Leaders in the Antihypertension Drug Market.(in Chinese)
        Fromhttp://www.menet.com.cn

    For more information, please contact:

    China Pharma Holdings, Inc.
     Diana Huang
     Tel:   +86-898-6681-1730
     Email: hps@chinapharmaholdings.com

    Or

    The Ruth Group
     Sara Ephraim
     Tel:   +1-646-536-7002
     Email: sephraim@theruthgroup.com

'/>"/>
SOURCE China Pharma Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
2. Syngenta Enters Into Research Collaboration With Anhui Academy, China
3. China Sky One Medical, Inc. CFO to Present at Roth Conference
4. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
5. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
6. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
7. China Biologic Products Enters into Short-Term Loan Agreement
8. China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin Enteric-Coated Capsules
9. American Oriental Bioengineering to Participate in the 2009 UBS Greater China Conference
10. China Sky One Medical, Inc. Qualifies for Preferential Income Tax Rate
11. Health Robotics Announces Partnership in the Peoples Republic of China With The Devon International Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016  Dr. Thomas P. McHugh ... The Woodlands, Texas , now offers ... of treated fat cells in just 25-minutes, leaving a ... 90 percent of Americans report feeling bothered by excess ... reduction procedures are a growing industry. This innovative new ...
(Date:5/2/2016)... YORK , May 2, 2016 ... announces that its technology partner Mannin Research Inc. will ... Ophthalmology (ARVO), which takes place from May 1-5, 2016 ... executives will be meeting with its vendors and research ... explore business development goals and other collaborative opportunities for ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... report on the pre-launch success of their revolutionary, veterinarian-designed product for indoor cats. ... stalk, trap, and play with their food the way nature intended. NoBowls make ...
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., a ... procedures, today announced the completion of a significant transaction and partnership that positions ... customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity ...
Breaking Biology Technology:
(Date:3/15/2016)... JERUSALEM , March 15, 2016 ... Jerusalem , the technology-transfer company of the Hebrew University, ... developer of remote sensing technology of various human biological ... funding, raising $2.0 million from private investors. ... technology, based on the detection of electromagnetic emissions from ...
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
(Date:3/11/2016)... PUNE, India , March 11, 2016 ... to a new market research report "Image Recognition Market ... by Application (Marketing and Advertising), by Deployment Type (On-Premises ... Global Forecast To 2022", published by MarketsandMarkets, the global ... in 2015 to USD 29.98 Billion by 2020, at ...
Breaking Biology News(10 mins):